�ݺ�ߣshows by User: HusseinAlkufi

�ݺ�ߣshows by User: HusseinAlkufi / http://www.slideshare.net/images/logo.gif �ݺ�ߣshows by User: HusseinAlkufi / Tue, 27 Apr 2021 09:14:06 GMT �ݺ�ߣShare feed for �ݺ�ߣshows by User: HusseinAlkufi Percentage and ratio strength /slideshow/percentage-and-ratio-strength/247112771 percentageandratiostrength-210427091406
Percentage, Ratio Strength, and Other Expressions of Concentration ]]>
Percentage, Ratio Strength, and Other Expressions of Concentration ]]> Tue, 27 Apr 2021 09:14:06 GMT /slideshow/percentage-and-ratio-strength/247112771 HusseinAlkufi@slideshare.net(HusseinAlkufi) Percentage and ratio strength HusseinAlkufi Percentage, Ratio Strength, and Other Expressions of Concentration <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/percentageandratiostrength-210427091406-thumbnail.jpg?width=120&height=120&fit=bounds" /> Percentage, Ratio Strength, and Other Expressions of Concentration

Percentage and ratio strength from Hussein Alkufi

]]> 3376 0 https://cdn.slidesharecdn.com/ss_thumbnails/percentageandratiostrength-210427091406-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post

http://activitystrea.ms/schema/1.0/posted

0 Milling part 2 2020 /slideshow/milling-part-2-2020/234982070 millingpart22020-200604091351
milling]]>
milling]]> Thu, 04 Jun 2020 09:13:50 GMT /slideshow/milling-part-2-2020/234982070 HusseinAlkufi@slideshare.net(HusseinAlkufi) Milling part 2 2020 HusseinAlkufi milling <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/millingpart22020-200604091351-thumbnail.jpg?width=120&height=120&fit=bounds" /> milling

Milling part 2 2020 from Hussein Alkufi

]]> 367 0 https://cdn.slidesharecdn.com/ss_thumbnails/millingpart22020-200604091351-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post

http://activitystrea.ms/schema/1.0/posted

0 Isotonic and buffer solutions /slideshow/isotonic-and-buffer-solutions/234754695 isotonicandbuffersolutions-200530114406
It is generally accepted that for ophthalmic and parenteral administration, isotonic solutions are better tolerated by the patient than those at the extremes of hypo- and hypertonicity. Most ophthalmic preparations are formulated to be isotonic. Injections that are not isotonic should be administered slowly and in small quantities to minimize tissue irritation, pain, and cell fluid imbalance. ]]>
It is generally accepted that for ophthalmic and parenteral administration, isotonic solutions are better tolerated by the patient than those at the extremes of hypo- and hypertonicity. Most ophthalmic preparations are formulated to be isotonic. Injections that are not isotonic should be administered slowly and in small quantities to minimize tissue irritation, pain, and cell fluid imbalance. ]]> Sat, 30 May 2020 11:44:06 GMT /slideshow/isotonic-and-buffer-solutions/234754695 HusseinAlkufi@slideshare.net(HusseinAlkufi) Isotonic and buffer solutions HusseinAlkufi It is generally accepted that for ophthalmic and parenteral administration, isotonic solutions are better tolerated by the patient than those at the extremes of hypo- and hypertonicity. Most ophthalmic preparations are formulated to be isotonic. Injections that are not isotonic should be administered slowly and in small quantities to minimize tissue irritation, pain, and cell fluid imbalance. <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/isotonicandbuffersolutions-200530114406-thumbnail.jpg?width=120&height=120&fit=bounds" /> It is generally accepted that for ophthalmic and parenteral administration, isotonic solutions are better tolerated by the patient than those at the extremes of hypo- and hypertonicity. Most ophthalmic preparations are formulated to be isotonic. Injections that are not isotonic should be administered slowly and in small quantities to minimize tissue irritation, pain, and cell fluid imbalance.

Isotonic and buffer solutions from Hussein Alkufi

]]> 1044 0 https://cdn.slidesharecdn.com/ss_thumbnails/isotonicandbuffersolutions-200530114406-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post

http://activitystrea.ms/schema/1.0/posted

0 Milling part 1 2020 /slideshow/milling-part-1-2020/234510257 millingpart12020-200523224343
milling ]]>
milling ]]> Sat, 23 May 2020 22:43:43 GMT /slideshow/milling-part-1-2020/234510257 HusseinAlkufi@slideshare.net(HusseinAlkufi) Milling part 1 2020 HusseinAlkufi milling <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/millingpart12020-200523224343-thumbnail.jpg?width=120&height=120&fit=bounds" /> milling

Milling part 1 2020 from Hussein Alkufi

]]> 261 3 https://cdn.slidesharecdn.com/ss_thumbnails/millingpart12020-200523224343-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post

http://activitystrea.ms/schema/1.0/posted

0 Mixing part 3 /slideshow/mixing-part-3/233918084 mixingpart3-200514092855
mixing part 3]]>
mixing part 3]]> Thu, 14 May 2020 09:28:55 GMT /slideshow/mixing-part-3/233918084 HusseinAlkufi@slideshare.net(HusseinAlkufi) Mixing part 3 HusseinAlkufi mixing part 3 <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/mixingpart3-200514092855-thumbnail.jpg?width=120&height=120&fit=bounds" /> mixing part 3

Mixing part 3 from Hussein Alkufi

]]> 288 0 https://cdn.slidesharecdn.com/ss_thumbnails/mixingpart3-200514092855-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post

http://activitystrea.ms/schema/1.0/posted

0 Mixing part 2 /slideshow/mixing-part-2/233917943 mixingpart2-200514092724
mixing part 2]]>
mixing part 2]]> Thu, 14 May 2020 09:27:24 GMT /slideshow/mixing-part-2/233917943 HusseinAlkufi@slideshare.net(HusseinAlkufi) Mixing part 2 HusseinAlkufi mixing part 2 <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/mixingpart2-200514092724-thumbnail.jpg?width=120&height=120&fit=bounds" /> mixing part 2

Mixing part 2 from Hussein Alkufi

]]> 225 0 https://cdn.slidesharecdn.com/ss_thumbnails/mixingpart2-200514092724-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post

http://activitystrea.ms/schema/1.0/posted

0 Mixing part 1 /slideshow/mixing-part-1-233917824/233917824 mixingpart1-200514092557
mixing]]>
mixing]]> Thu, 14 May 2020 09:25:57 GMT /slideshow/mixing-part-1-233917824/233917824 HusseinAlkufi@slideshare.net(HusseinAlkufi) Mixing part 1 HusseinAlkufi mixing <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/mixingpart1-200514092557-thumbnail.jpg?width=120&height=120&fit=bounds" /> mixing

Mixing part 1 from Hussein Alkufi

]]> 304 0 https://cdn.slidesharecdn.com/ss_thumbnails/mixingpart1-200514092557-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post

http://activitystrea.ms/schema/1.0/posted

0 Formulation and Evaluation of Sustained Release Sumatriptan Mucoadhesive Intranasal in-Situ Gel /slideshow/formulation-and-evaluation-of-sustained-release-sumatriptan-mucoadhesive-intranasal-insitu-gel/233916684 926-articletext-4545-1-10-20191222-200514091444
Sumatriptan(ST) is a selective agonist at serotonin 5-HTI receptors, as well as 5-HT1B/1D subtypes. It is effective for acute migraine attacks, but has a short half life (about 2 hours) and low oral bioavailability (15%). The purpose of this study was to develop and optimize nasal mucoadhesive in-situ gel(IG) of ST to enhance nasal residence time for migraine management. Cold method was used to prepare different formulas of ST nasal IG, using thermosensitive polymers (poloxamer 407 alone or with poloxamer 188) with a mucoadhesive polymer hyaluronic acid (HA) which were examined for gelation temperature and gelation time, pH, drug content, gel strength, spreadability, mucoadhesive force determination, viscosity, in-vitro drug release, and the selected formula was subjected to fourier transform infrared (FTIR) compatibility studies, and to ex-vivo permeation study, histological evaluation of the sheep mucosal tissue after ST nasal gel application for 6 hours.]]>
Sumatriptan(ST) is a selective agonist at serotonin 5-HTI receptors, as well as 5-HT1B/1D subtypes. It is effective for acute migraine attacks, but has a short half life (about 2 hours) and low oral bioavailability (15%). The purpose of this study was to develop and optimize nasal mucoadhesive in-situ gel(IG) of ST to enhance nasal residence time for migraine management. Cold method was used to prepare different formulas of ST nasal IG, using thermosensitive polymers (poloxamer 407 alone or with poloxamer 188) with a mucoadhesive polymer hyaluronic acid (HA) which were examined for gelation temperature and gelation time, pH, drug content, gel strength, spreadability, mucoadhesive force determination, viscosity, in-vitro drug release, and the selected formula was subjected to fourier transform infrared (FTIR) compatibility studies, and to ex-vivo permeation study, histological evaluation of the sheep mucosal tissue after ST nasal gel application for 6 hours.]]> Thu, 14 May 2020 09:14:44 GMT /slideshow/formulation-and-evaluation-of-sustained-release-sumatriptan-mucoadhesive-intranasal-insitu-gel/233916684 HusseinAlkufi@slideshare.net(HusseinAlkufi) Formulation and Evaluation of Sustained Release Sumatriptan Mucoadhesive Intranasal in-Situ Gel HusseinAlkufi Sumatriptan(ST) is a selective agonist at serotonin 5-HTI receptors, as well as 5-HT1B/1D subtypes. It is effective for acute migraine attacks, but has a short half life (about 2 hours) and low oral bioavailability (15%). The purpose of this study was to develop and optimize nasal mucoadhesive in-situ gel(IG) of ST to enhance nasal residence time for migraine management. Cold method was used to prepare different formulas of ST nasal IG, using thermosensitive polymers (poloxamer 407 alone or with poloxamer 188) with a mucoadhesive polymer hyaluronic acid (HA) which were examined for gelation temperature and gelation time, pH, drug content, gel strength, spreadability, mucoadhesive force determination, viscosity, in-vitro drug release, and the selected formula was subjected to fourier transform infrared (FTIR) compatibility studies, and to ex-vivo permeation study, histological evaluation of the sheep mucosal tissue after ST nasal gel application for 6 hours. <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/926-articletext-4545-1-10-20191222-200514091444-thumbnail.jpg?width=120&height=120&fit=bounds" /> Sumatriptan(ST) is a selective agonist at serotonin 5-HTI receptors, as well as 5-HT1B/1D subtypes. It is effective for acute migraine attacks, but has a short half life (about 2 hours) and low oral bioavailability (15%). The purpose of this study was to develop and optimize nasal mucoadhesive in-situ gel(IG) of ST to enhance nasal residence time for migraine management. Cold method was used to prepare different formulas of ST nasal IG, using thermosensitive polymers (poloxamer 407 alone or with poloxamer 188) with a mucoadhesive polymer hyaluronic acid (HA) which were examined for gelation temperature and gelation time, pH, drug content, gel strength, spreadability, mucoadhesive force determination, viscosity, in-vitro drug release, and the selected formula was subjected to fourier transform infrared (FTIR) compatibility studies, and to ex-vivo permeation study, histological evaluation of the sheep mucosal tissue after ST nasal gel application for 6 hours.

Formulation and Evaluation of Sustained Release Sumatriptan Mucoadhesive Intranasal in-Situ Gel from Hussein Alkufi

]]> 52 0 https://cdn.slidesharecdn.com/ss_thumbnails/926-articletext-4545-1-10-20191222-200514091444-thumbnail.jpg?width=120&height=120&fit=bounds document Black http://activitystrea.ms/schema/1.0/post

http://activitystrea.ms/schema/1.0/posted

0 Determination the Levels of Zinc and Copper in Patients with Leukemia /slideshow/determination-the-levels-of-zinc-and-copper-in-patients-with-leukemia/143130636 husseinalkufi-190502000126
Leukemia is the most common type of blood cancer in which both of zinc and copper levels are altered resulting in many metabolic and physiological disorders.]]>
Leukemia is the most common type of blood cancer in which both of zinc and copper levels are altered resulting in many metabolic and physiological disorders.]]> Thu, 02 May 2019 00:01:26 GMT /slideshow/determination-the-levels-of-zinc-and-copper-in-patients-with-leukemia/143130636 HusseinAlkufi@slideshare.net(HusseinAlkufi) Determination the Levels of Zinc and Copper in Patients with Leukemia HusseinAlkufi Leukemia is the most common type of blood cancer in which both of zinc and copper levels are altered resulting in many metabolic and physiological disorders. <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/husseinalkufi-190502000126-thumbnail.jpg?width=120&height=120&fit=bounds" /> Leukemia is the most common type of blood cancer in which both of zinc and copper levels are altered resulting in many metabolic and physiological disorders.

Determination the Levels of Zinc and Copper in Patients with Leukemia from Hussein Alkufi

]]> 82 2 https://cdn.slidesharecdn.com/ss_thumbnails/husseinalkufi-190502000126-thumbnail.jpg?width=120&height=120&fit=bounds document Black http://activitystrea.ms/schema/1.0/post

http://activitystrea.ms/schema/1.0/posted

0 https://cdn.slidesharecdn.com/profile-photo-HusseinAlkufi-48x48.jpg?cb=1733828902 pharmacist ph.hussein.alkufi@gmail.com https://cdn.slidesharecdn.com/ss_thumbnails/percentageandratiostrength-210427091406-thumbnail.jpg?width=320&height=320&fit=bounds slideshow/percentage-and-ratio-strength/247112771 Percentage and ratio s... https://cdn.slidesharecdn.com/ss_thumbnails/millingpart22020-200604091351-thumbnail.jpg?width=320&height=320&fit=bounds slideshow/milling-part-2-2020/234982070 Milling part 2 2020 https://cdn.slidesharecdn.com/ss_thumbnails/isotonicandbuffersolutions-200530114406-thumbnail.jpg?width=320&height=320&fit=bounds slideshow/isotonic-and-buffer-solutions/234754695 Isotonic and buffer so...